Tower Research Capital (TRC)’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-3,724
| Closed | -$24K | – | 6658 |
|
|
2022
Q4 | $24K | Sell |
3,724
-28,574
| -88% | -$158K | ﹤0.01% | 2983 |
|
|
2022
Q3 | $165K | Buy |
+32,298
| New | +$203K | ﹤0.01% | 2113 |
|
|
2022
Q2 | – | Sell |
-3,065
| Closed | -$11K | – | 6864 |
|
|
2022
Q1 | $11K | Sell |
3,065
-7,680
| -71% | -$28.4K | ﹤0.01% | 4250 |
|
|
2021
Q4 | $54K | Buy |
10,745
+10,574
| +6,184% | +$63.8K | ﹤0.01% | 2716 |
|
|
2021
Q3 | $1K | Buy |
+171
| New | +$1.17K | ﹤0.01% | 5615 |
|
|
2020
Q4 | – | Sell |
-1,553
| Closed | -$8K | – | 5506 |
|
|
2020
Q3 | $8K | Sell |
1,553
-406
| -21% | -$2.43K | ﹤0.01% | 4210 |
|
|
2020
Q2 | $11K | Buy |
+1,959
| New | +$11.3K | ﹤0.01% | 3987 |
|
|
2019
Q3 | – | Sell |
-1,507
| Closed | -$22K | – | 4667 |
|
|
2019
Q2 | $22K | Buy |
1,507
+1,171
| +349% | +$31.4K | ﹤0.01% | 2133 |
|
|
2019
Q1 | $14K | Buy |
+336
| New | +$14.2K | ﹤0.01% | 2494 |
|
|
2018
Q4 | – | Sell |
-155
| Closed | -$7K | – | 4530 |
|
|
2018
Q3 | $7K | Buy |
+155
| New | +$7.76K | ﹤0.01% | 2985 |
|
|
2018
Q2 | – | Sell |
-61
| Closed | -$4K | – | 4213 |
|
|
2018
Q1 | $4K | Buy |
61
+42
| +221% | +$2.22K | ﹤0.01% | 2820 |
|
|
2017
Q4 | $1K | Sell |
19
-31
| -62% | -$1.84K | ﹤0.01% | 3394 |
|
|
2017
Q3 | $3K | Buy |
+50
| New | +$2.86K | ﹤0.01% | 3507 |
|
|
2016
Q4 | – | Sell |
-177
| Closed | -$8K | – | 4561 |
|
|
2016
Q3 | $8K | Sell |
177
-219
| -55% | -$9.44K | ﹤0.01% | 2250 |
|
|
2016
Q2 | $15K | Buy |
+396
| New | +$16.9K | ﹤0.01% | 2494 |
|
Tower Research Capital (TRC)'s FSTX Position: Q1 2023 in Review
Tower Research Capital (TRC) sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 3,724 shares — an estimated $24K sold.
Tower Research Capital (TRC) first reported a position in FSTX in Q2 2016 and held it in 15 quarters. The position peaked at $165K in Q3 2022. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.
- Tower Research Capital (TRC) reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- Tower Research Capital (TRC) sold 3,724 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $24K.
- Tower Research Capital (TRC) first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2016 and held it in 15 quarters.
- Tower Research Capital (TRC)'s F-star Therapeutics, Inc. Common Stock position peaked at $165K in Q3 2022.
- 0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2023, filed 9 May 2023.